Published :
Updated :
For all latest news, follow The Financial Express Google News channel.
Al-Madina Pharmaceuticals will begin share trading on the SME Platform of the Dhaka Stock Exchange and Chittagong Stock Exchange on Monday.
The veterinary drug manufacturer raised Tk 50 million through qualified investors offer (QIO) early this month to expand business and repay bank loans.
Earlier on February 1, the Bangladesh Securities and Exchange Commission allowed it to raise the said amount through issuing 5 million ordinary shares at a face value of Tk 10 each.
The drug maker’s profit after tax, however, dropped 6 per cent to Tk 17.39 million in July-December 2022 compared to Tk 18.48 million in the same period a year before.
Its basic earnings per share (EPS) stood at Tk 1.13 for the six months through December 2022 as against basic EPS of Tk 1.24 for the same period of the previous year.
However, post-QIO basic EPS would be Tk 0.85 for July-December 2022 and net asset value (NAV) per share with revaluation would be Tk 19.65.
Al-Madina Pharma will not be able to declare any stock dividend for three years from its stock market listing, as per the BSEC condition.
Incorporated in July 2006, Al-Madina Pharmaceuticals manufactures more than 150 veterinary drugs and imports more than 70 human drugs. Its factory is situated at Tongi in Gazipur.